What biotech gets wrong about the "risk-based" QMS
Updated: May 9
Why risk management is one of the most misunderstood components of biotech’s QMS landscape.
When foundational QMS guidelines define risk as "the combination of the probability of occurrence of harm and the severity of that harm" (ref. ICH Q9), risk management becomes a product-centric consideration. However, industry experts recognize that this narrow interpretation is causing organizations to fail in applying risk management across process-level governance - above and beyond direct product realization.
Risk management is no longer a theoretical nicety that separates good from great. Regulators now expect risk-based thinking to be a staple across all decision-making workflows and a keystone of your QMS strategy.
This modern, risk-based QMS principle is increasingly targeted by regulators and Notified Bodies when assessing the QMS maturity of your organization. Where risk management is underdeveloped or underutilized, operational gaps persist, compound, and can ultimately lead to product quality issues and process performance stagnation.
If you see these patterns, your risk management paradigm may be overdue for a refresher:
Data selection bias that supports predetermined conclusions
Decisions shaped by personal preference (or self preservation) over objective evidence
Devotion to past precedence as a substitute for objective analysis
Is risk management an active component of your QMS or is it just a term used to feign QMS maturity?
Recommended Reading:
